FOSUN PHARMA (600196.SH) has announced that its subsidiary, Chongqing Yaoyou Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the drug registration application of Sodium Nitroprusside Injection. The approved indications for the injection are (1) hypertensive emergencies, such as hypertensive crisis, hypertensive encephalopathy, malignant hypertension, and paroxysmal hypertension during the perioperative period of pheochromocytoma; it may also be used for controlled hypotension during surgical anesthesia. (2) Acute heart failure, including acute pulmonary edema, as well as acute heart failure associated with acute myocardial infarction or valvular (mitral or aortic) insufficiency.